Eli Lilly temporarily paused clinical trials for its coronavirus antibody treatment yesterday, citing potential safety concerns raised by an independent review board. Additional detail on the decision was not provided. Lilly is the latest pharmaceutical company to pause clinical trials for a coronavirus treatment or vaccine, joining Johnson & Johnson (which paused its vaccine trial yesterday), and AstraZeneca (which paused its vaccine trial in September before resuming them the following week).
The New Paper
This story is from the October 14, 2020 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.
